Extract

This randomized phase II trial studies how well WEE1 inhibitor AZD1775 with or without cytarabine works in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has spread to other places in the body and usually cannot be cured or controlled with treatment. WEE1 inhibitor AZD1775 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving WEE1 inhibitor AZD1775 works better with or without cytarabine in treating patients with advanced acute myeloid leukemia or myelodysplastic syndrome.

Inclusion criteria

• Chronic myelomonocytic leukemia,Myelodysplastic Syndrome With Isolated Del(5q),Myelodysplastic/Myeloproliferative Neoplasm,Previously Treated Myelodysplastic Syndrome,Recurrent Adult Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia

Links

• nct
• ictrp